23.05.2023 17:30:04

Result of Annual General Meeting

Arix Bioscience PLC (ARIX)
Result of Annual General Meeting

23-May-2023 / 16:30 GMT/BST

 

Arix Bioscience plc

 

Result of Annual General Meeting

 

LONDON, 23 May 2023: Arix Bioscience plc (Arix or the Company) (LSE: ARIX), a transatlantic venture capital company focused on investing in breakthrough biotechnology companies, announces that at its Annual General Meeting (the "Meeting") duly convened and held today, all resolutions as set out on the notice of meeting were duly passed by way of a poll. Resolutions 1 to 11 were passed as ordinary resolutions. Resolutions 12 to 15 were passed as special resolutions.

 

Full details of the poll results are set out below and will also be available on the Company's .

 

No

RESOLUTION

VOTES FOR

%

VOTES AGAINST

%

TOTAL VOTES

% of ISC VOTED

VOTES WITHHELD

1

To receive the Directors' Report and the accounts of the Company for the year ended 31 December 2022

68,931,411

100.00%

3,441

0.00%

 

68,934,852

 

 

53.28%

 

 

8,440

 

2

To approve the Directors' Remuneration Report

61,073,950

 

89.25%

 

 

7,358,207

 

 

10.75%

 

68,432,157

 

52.89%

 

 

511,135

 

3

To re-elect Peregrine Moncreiffe as a Director

68,099,019

 

98.79%

 

 

834,821

 

 

1.21%

 

68,933,840

 

53.28%

 

 

9,452

 

4

To re-elect Maureen O'Connell as a Director

68,894,053

 

99.94%

 

 

42,077

 

 

0.06%

 

68,936,130

 

53.28%

 

 

7,162

 

5

To re-elect Isaac Kohlberg as a Director

68,900,656

 

99.98%

 

 

17,184

 

 

0.02%

 

68,917,840

 

53.26%

 

 

25,452

 

6

To re-elect Robert Lyne as a Director

 

68,902,689

 

 

99.95%

 

 

31,595

 

 

0.05%

 

68,934,284

 

53.28%

 

 

9,008

 

7

To elect Dr. Debra Barker as a Director

68,907,528

 

99.95%

 

 

32,248

 

 

0.05%

 

68,939,776

 

53.28%

 

 

3,516

 

8

To elect Andrew Smith as a Director

 

68,921,195

 

 

99.98%

 

 

13,089

 

 

0.02%

 

68,934,284

 

53.28%

 

 

9,008

 

9

To appoint BDO LLP as auditors of the Company

68,929,881

 

99.99%

 

 

7,445

 

 

0.01%

 

68,937,326

 

53.28%

 

 

5,966

 

10

To authorise the Audit and Risk Committee of the Company to fix the auditor's remuneration

68,934,245

 

100.00%

 

 

2,013

 

 

0.00%

 

68,936,258

 

53.28%

 

 

7,034

 

11

To authorise the Directors to allot shares

65,989,256

 

95.72%

 

 

2,950,520

 

 

4.28%

 

68,939,776

 

53.28%

 

 

3,516

 

12

Authority to disapply statutory pre emption rights

62,199,252

 

90.23%

 

 

6,734.680

 

 

9.77%

 

68,933,932

 

53.28%

 

 

9,360

 

13

Additional authority to disapply statutory pre emption rights

62,202,105

 

90.23%

 

 

6,731,827

 

9.77%

68,933,932

 

53.28%

 

 

9,360

 

14

To authorise the Company to purchase its own shares

68,921,128

 

99.98%

 

 

17,177

 

 

0.02%

 

 

68,938,305

 

 

53.28%

 

 

4,987

 

15

Authority to call a general meeting, other than an annual general meeting, on not less than 14 clear days' notice

68,145,351

 

98.85%

 

 

792,954

 

 

1.15%

 

68,938,305

 

53.28%

 

 

4,987

 

 

In accordance with Listing Rule 9.6.2, copies of resolutions passed at the Meeting concerning items other than ordinary business will shortly be available for inspection on the National Storage Mechanism, which can be accessed at .

The full text of the resolutions considered at the AGM are contained in the Notice of AGM, published on 25 April 2023, which is available on Arix investor relations .

[ENDS]

 

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

 

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

arix@powerscourt-group.com

 

About Arix Bioscience plc

Arix Bioscience plc is a transatlantic venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 


Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
ISIN: GB00BD045071
Category Code: RAG
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 245804
EQS News ID: 1639935

 
End of Announcement EQS News Service

fncls.ssp?fn=show_t_gif&application_id=1639935&application_name=news&site_id=smarthouse

Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!

Nachrichten zu Arix Bioscience PLC Registered Shsmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Arix Bioscience PLC Registered Shsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Newssuche

GO

Börse aktuell - Live Ticker

Dow schlussendlich tiefer -- ATX und DAX verabschieden sich stärker ins Wochenende -- Asiens Börsen schließen uneinig
Die US-Börsen zeigten sich vor dem Wochenende deutlich schwächer. Der heimische und deutsche Aktienmarkt notierten am Freitag im Plus. Die asiatischen Aktienmärkte präsentierten sich am Freitag uneins.

Nachrichten

Aktien ATX  DAX  EuroStoxx 50  Dow Jones  NASDAQ 100  Nikkei 225  S&P 500 

Kontakt  - Impressum - Werbung

Sitemap  - Datenschutz  - Disclaimer  - AGB  - Privatsphäre-Einstellungen